The Hill: FDA approves cholesterol drug with $15,000 yearly price tag

07-24-2015 Media

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but its price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years,” John Rother, president of the National Coalition on Health Care, said in a statement.

PRESS STATEMENT: FDA Approves Praluent, New Cholesterol-Lowering Treatment

07-24-2015 Blog PostsPress Release

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.”

Drug Companies Pushed From Far and Wide to Explain High Prices

07-23-2015 Media

As complaints grow about exorbitant drug prices, pharmaceutical companies are coming under pressure to disclose the development costs and profits of those medicines and the rationale for charging what they do.

Doctors Object to High Cancer-Drug Prices

07-23-2015 Media

Amid the growing clamor, cancer medication has drawn particular ire. The average price of new cancer drugs in the U.S. increased five- to tenfold over 15 years, to more than $100,000 a year in 2012, according to the Mayo Clinic journal editorial.

Cancer experts call for curbs on rising drug prices

07-23-2015 Media

In recent years, increasingly specialized medications and an aging population that takes more drugs have substantially boosted the price of treatments for cancer, hepatitis C, cystic fibrosis and other diseases.

PwC Infographic: Costs from specialty drugs skyrocketing

06-29-2015 Media

A new PricewaterhouseCoopers report on medical cost trends highlights how specialty drugs are outpacing traditional drugs in a major way.

Skyrocketing specialty drug cost hurts wallets

06-25-2015 Media

The rising cost of specialty drugs to treat complex, chronic or life-threatening conditions has the potential to break the pocket books of businesses, consumers, insurance companies and the state, according to Milam Ford of Blue Cross and Blue Shield of Louisiana.

How to Lower Specialty Drug Prices

06-22-2015 Media

We need to make clear that monopoly grants come with responsibility and accountability, and that competition is more important to the public than a blank check for innovation we cannot afford.

PRESS STATEMENT: New Kaiser Family Foundation Poll Reinforces Need for Sustainable Drug Pricing

06-16-2015 Blog PostsPress Release

John Rother, President of the National Coalition on Health Care and Chair of the Campaign for Sustainable Rx Pricing issued the following statement in response to a recent health tracking poll by the Kaiser Family Foundation that found that an overwhelming 76% of Americans blame pharmaceutical companies for the rising cost of medicines.

Skyrocketing drug prices leave cures out of reach for some patients

06-16-2015 Media

Sophisticated drugs are opening the door, scientists say, to an era of “precision medicine.” They’re also ushering in an age of astronomical prices.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.